Bristol Myers Squibb’s (BMY) Lisocabtagene maraleucel, proposed for the treatment of adults with relapsed or refractory (R/R) large B-cell lymphoma after at least two prior therapies, awaits the FDA decision on November 16, 2020.Lisocabtagene Maraleucel, also known as Liso-cel, is an investigational chimeric antigen receptor (CAR) T-cell therapy designed to target CD19, which is a surface glycoprotein expressed during normal B-cell development and maintained following malignant transformation of B cells.If approved, Liso-cel would compete with the two FDA-approved CAR T-cell therapies for large B-cell lymphoma namely Novartis’ Kymriah and Gilead Sciences’ Yescarta.According to a report compiled by GlobalData, Liso-cel is expected to achieve peak sales of $1.3 billion in 2026.BMY closed Friday’s (Oct.23, 2020) trading at $60.13, down 1.04%.